Endonovo Therape (ENDV) Stock Price, News & Analysis
Company Description
Endonovo Therape (OTC Link: ENDV) is classified in the biotechnology industry within the Healthcare sector and carries a market capitalization of $144.6K.
ENDV has declined 50.0% over the past year. Shares last traded at $0.0001.
For FY2022, Endonovo Therape reported revenue of $135K.
This page collects what Stock Titan holds for ENDV, including price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Endonovo Therape (ENDV) stock last closed at $0.0001. Over the past 12 months, the stock has lost 50.0%. At a market capitalization of $144.6K, ENDV is classified as a micro-cap stock with approximately 1.8B shares outstanding.
Latest News
Endonovo Therape has 10 recent news articles. Of the recent coverage, 2 articles coincided with positive price movement and 6 with negative movement. Key topics include fda approval, clinical trial, partnership. View all ENDV news →
SEC Filings
Financial Highlights
Endonovo Therape generated $135K in revenue in FY2022, retaining a 92.6% gross margin, and operating income reached -$3.3M (-2411.7% operating margin). The company generated -$679K in operating cash flow. With a current ratio of 0.00, short-term liquidity bears monitoring.
Upcoming Events
Short Interest History
Days to Cover History
ENDV Company Profile & Sector Positioning
Endonovo Therape (ENDV) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the OTC Link.
Investors comparing ENDV often look at related companies in the same sector, including Globestar Therapeutics Corp (GSTC), Tracon Pharmaceu (TCON), Trevena Inc (TRVN), Scorpius Holdings (SCPX), and Vincerx Pharma Inc (VINC). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate ENDV's relative position within its industry.